Decision-making by p53 and mTOR.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. HIV infection in microglia leads to senescence, triggering activation of neurotoxicity pathways.bioRxiv : the preprint server for biology · 2025
   Article
2. mTOR acts as a pivotal signaling hub for neural crest cells during craniofacial development.PLoS genetics · 2018
   Article
3. The IGF-1R/AKT pathway determines cell fate in response to p53.Translational cancer research · 2016
   Article
4. mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling.Apoptosis : an international journal on programmed cell death · 2015
   Article
5. p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3.Cell cycle (Georgetown, Tex.) · 2012
   Article
6. Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging.Aging · 2012
   Article
7. Advances in targeting signal transduction pathways.Oncotarget · 2012
   Review
8. Rapalogs in cancer prevention: anti-aging or anticancer?Cancer biology & therapy · 2012
   Review
9. Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine.Cell cycle (Georgetown, Tex.) · 2012
   Article
10. Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes.Oncotarget · 2012
    Review
11. Answering the ultimate question "what is the proximal cause of aging?".Aging · 2012
    Review
12. Recent discoveries in the cycling, growing and aging of the p53 field.Aging · 2012
    Review
13. Controversial aspects of oncogene-induced senescence.Cell cycle (Georgetown, Tex.) · 2012
    Review
14. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Oncotarget · 2012
    Review
15. Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells.Oncotarget · 2012
    Article
16. Regulation of glucose metabolism by p53: emerging new roles for the tumor suppressor.Oncotarget · 2011
    Review
17. Molecular links between cellular senescence, longevity and age-related diseases - a systems biology perspective.Aging · 2011
    Article
18. The Regulation of Aging and Longevity: A New and Complex Role of p53.Genes & cancer · 2011
    Article
19. Be quiet and you'll keep young: does mTOR underlie p53 action in protecting against senescence by favoring quiescence?Aging · 2011
    Article

Corrections and comments

• Comment on
  The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway.2010

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as